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Abstract
Human mesenchymal stem cells (hMSCs) are multipotent cells capable of differentiating into a variety of mature cell types,
including osteoblasts, adipocytes and chondrocytes. It has previously been shown that, when expanded in medium
supplemented with fibroblast growth factor-2 (FGF-2), hMSCs show enhanced chondrogenesis (CG). Previous work
concluded that the enhancement of CG could be attributed to the selection of a cell subpopulation with inherent
chondrogenic potential. In this study, we show that FGF-2 pretreatment actually primed hMSCs to undergo enhanced CG by
increasing basal Sox9 protein levels. Our results show that Sox9 protein levels were elevated within 30 minutes of exposure
to FGF-2 and progressively increased with longer exposures. Further, we show using flow cytometry that FGF-2 increased
Sox9 protein levels per cell in proliferating and non-proliferating hMSCs, strongly suggesting that FGF-2 primes hMSCs for
subsequent CG by regulating Sox9. Indeed, when hMSCs were exposed to FGF-2 for 2 hours and subsequently
differentiated into the chondrogenic lineage using pellet culture, phosphorylated-Sox9 (pSox9) protein levels became
elevated and ultimately resulted in an enhancement of CG. However, small interfering RNA (siRNA)-mediated knockdown of
Sox9 during hMSC expansion was unable to negate the prochondrogenic effects of FGF-2, suggesting that the FGF-2-
mediated enhancement of hMSC CG is only partly regulated through Sox9. Our findings provide new insights into the
mechanism by which FGF-2 regulates predifferentiation hMSCs to undergo enhanced CG.
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Introduction
Due to the limited capacity of articular cartilage for self repair
and lack of effective treatments for cartilage injuries and
degenerative joint diseases like osteoarthritis [1], tissue engineering
has gained considerable attention as a promising approach to
cartilage repair. Tissue engineering approaches aim to recapitulate
normal developmental and tissue healing processes to drive tissue
regeneration. For tissue engineering strategies to be successful, an
appropriate cell source must be instructed to proliferate and then
differentiate by specific bioactive cues, such as growth factors and
extracellular matrix molecules. Human mesenchymal stem cells
(hMSCs) provide an attractive cell source for cartilage tissue
engineering applications, as they are readily expandable [2] and
capable of differentiating into chondrocytes [3]. However, hMSCs
represent a heterogeneous population of cells with varying
chondrogenic potential [4,5], thus limiting their use in cartilage
tissue engineering applications. In addition, hMSCs fail to produce
the quality or quantity of cartilage matrix compared to articular
chondrocytes under identical conditions [6]. Thus, improvements
to our current expansion conditions will be necessary to purify
those hMSCs with greatest chondrogenic potential and/or
enhance their ability to undergo chondrogenesis (CG) if cartilage
tissue engineering using hMSCs is to be of clinical relevance.
Fibroblast growth factor-2 (FGF-2) is one of over 20 members of
the large FGF family of heparin-binding polypeptide growth
factors. FGF-2 acts as a potent mitogen for several cell types of
mesenchymal origin [7,8,9]. In addition, FGF-2 has been
implicated in the regulation of several key signaling cascades
involved in the development and maintenance of cartilage,
including the earliest stages of limb development [10,11]. In vitro,
it has previously been shown that, when expanded in culture
medium supplemented with FGF-2, hMSCs show enhanced
chondrogenic potential [8]. It is unclear, however, how FGF-2
enhances the CG of hMSCs. Two potential mechanisms may be
operating individually or in tandem: FGF-2 treatment may select a
subpopulation of hMSCs with inherent chondrogenic potential to
proliferate (referred to as selection) [12]; or FGF-2 may change the
molecular machinery of the entire population or a subset of the
population in some way to more efficiently respond to chondro-
genic cues, thus enhancing subsequent differentiation (referred to
as priming) [5].
Previous work has suggested that, in response to FGF-2, hMSC
CG is enhanced through the selection of an immature stem cell
population with inherent multipotentiality, as FGF-2 had equally
potent effects in enhancing hMSC osteogenesis [13] and
adipogenesis [14]. Additionally, it was shown that expansion of
hMSCs in FGF-2-supplemented medium led to an initial increase
in average telomere length without detectable telomerase activity,
suggesting that FGF-2 selects for the survival and expansion of a
subset of cells enriched in multipotent precursors [12]. While these
studies present a convincing case for a selection-based mechanism
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suggested greater complexity beyond simply the selection of a
multipotential stem cell population. For instance, Adesida et al.
reported that the redifferentiation of dedifferentiated chondro-
cytes, a presumably homogeneous cell population, is greatly
enhanced by expansion in FGF-2, as well. In fact, FGF-2
enhanced the re-expression of collagen type II (Col II) 200-fold upon
subsequent differentiation in pellet culture [15].
Sox9, an SRY-related transcription factor harboring the
conserved high-mobility group DNA-binding domain, is required
for successive steps of cartilage formation during development. At
early stages, Sox9 functions to initiate chondrogenic lineage
specification in a population of mesenchymal precursor cells that
condense to form precartilaginous buds [16]. Inactivation of Sox9
in precursor cells prior to condensation leads to the complete
absence of cartilage formation [17]. Later during development,
Sox9 binds directly to regulatory elements of cartilage-specific
genes, such as Col II and aggrecan (AGN), to drive chondrogenic
differentiation [18,19]. Sox9 also activates the expression of L-Sox5
and Sox6 [17], transcriptional co-activators that are likewise
required for articular cartilage formation [20].
In the current study, we investigated further the mechanism
underlying the observed FGF-2-mediated enhancement of CG.
We begin by offering new insights into the nature by which the
FGF-2-treated hMSC population is modulated after long-term
exposure and extend upon these findings to show that 2 hours of
exposure to FGF-2 was sufficient to enhance hMSC CG, thus
suggesting a priming-based mechanism for the observed enhance-
ment of CG. FGF-2 increased basal Sox9 protein levels in hMSCs
within 30 minutes, and continued exposure to FGF-2 led to
progressively increased Sox9 protein levels. Importantly, FGF-2
increased Sox9 protein levels in both proliferating and non-
proliferating hMSCs, further suggesting that FGF-2 primes
hMSCs for subsequent CG by regulating Sox9. However, small
interfering RNA (siRNA)-mediated knockdown of Sox9 was
unable to negate the enhancement of CG induced by FGF-2,
suggesting that FGF-2 enhances hMSC CG only partly through
Sox9. Nonetheless, FGF-2 was a potent inducer of Sox9
expression and there is a strong correlation between Sox9 levels
prior to CG and the effectiveness of differentiation.
Results
FGF-2 enhances hMSC CG and modulates lineage-
specific transcription factor expression
Expanding hMSCs in medium supplemented with FGF-2
enhanced subsequent differentiation into the chondrogenic lineage
compared to non-FGF-2-supplemented controls, as evidenced by
the upregulation of cartilage-specific gene expression (Fig. 1A) and
GAG accumulation (Fig. 1B). Specifically, both hMSCs expanded
for 2 passages in 5%- (Fig. 1A; Lane 2) and 1% FBS+FGF-2
(Fig. 1A; Lane 4) showed upregulated cartilage-specific gene
expression compared to cells expanded in 10% FBS (Fig. 1A; Lane
1), the current gold standard for hMSC expansion, upon
chondrogenic induction at each time point. Importantly, Col II
showed relatively high gene expression as early as Day 7 in both
FGF-2-expanded cultures, whereas Col II expression was not
detected until Day 14 in 10% FBS-expanded cells and Day 21 in
5% FBS-expanded cells (Fig. 1A; Lane 3). Similarly, collagen type IX
(Col IX) was expressed at detectable levels earlier in both FGF-2-
expanded cultures, appearing at Days 7 and 14 in 5%- and 1%
FBS+FGF-2-expanded cells, respectively. Strikingly, Col IX was
not expressed at detectable levels even at Day 21 of differentiation
in either of the non-FGF-2-expanded hMSC populations. Similar
trends were observed when quantifying GAG accumulation
normalized to DNA content within chondrogenic pellets
(Fig. 1B). After 21 days of differentiation, both FGF-2-expanded
hMSC populations produced significantly more GAG (86.6 and
66.9 mg GAG/mg DNA) than the non-FGF-2-expanded control
cells (22.4 and 34.5 mg GAG/mg DNA) (p,0.05). These data
clearly demonstrate that FGF-2 has potent effects in enhancing the
chondrogenic potential of predifferentiation hMSCs.
To investigate the nature by which FGF-2 alters the phenotype
of hMSCs prior to chondrogenic induction, hMSCs were
expanded in medium containing 5% FBS with or without FGF-
2 for 2 passages and analyzed for gene and protein expression
using real-time RT-PCR and Western blotting, respectively.
Human MSCs maintained in FGF-2-supplemented medium
showed greatly modulated gene expression prior to chondrogenic
differentiation (Fig. 2A–C). Specifically, FGF-2 significantly
downregulated Oct3/4 and Nanog, stem cell pluripotency markers
(Fig. 2A), upregulated Sox9 and PPARc2, transcription factors that
regulate chondrogenic- and adipogenic-specific gene expression
(Fig. 2B), and downregulated Runx2, a transcription factor that
regulates osteogenic-specific gene expression (Fig. 2B). In addition,
FGF-2 led to the dramatic upregulation of L-Sox5 expression,
which showed a 292-fold increase in mRNA transcript levels
(Fig. 2C). Importantly, the observed upregulation in Sox9 gene
expression with FGF-2 supplementation translated to an increase
in Sox9 protein levels after expansion for 2 passages (Fig. 2D).
Upon chondrogenic induction in pellet culture, phosphorylated-
Sox9 (pSox9) protein levels became elevated 12 hours after pellet
formation in hMSCs expanded in FGF-2 (Fig. 2D). Together,
Figure 1. FGF-2 enhances hMSC CG. Human MSCs were expanded
in varying concentrations of FBS with or without FGF-2 for 2 passages
prior to CG and analyzed for cartilaginous properties upon differenti-
ation in pellet culture. (A) End-point RT-PCR analysis showed that
cartilage-specific gene expression was upregulated in the 2 FGF-2-
expanded conditions (Lanes 2 and 4) at each time point compared to
those without FGF-2 pretreatment (Lanes 1 and 3). Lane 1: 10% FBS;
Lane 2: 5% FBS+FGF-2; Lane 3: 5% FBS; Lane 4: 1% FBS+FGF-2. (B)
Significantly greater GAG accumulation was observed in the 2 FGF-2-
expanded conditions at each time point compared to those without
FGF-2 pretreatment. GAG content was normalized to DNA content.
Values are mean 6 SD. All conditions were significant with each other
except the 2 FGF-2-expanded conditions at Day 21. p,0.05, n=3.
doi:10.1371/journal.pone.0022887.g001
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multipotent state and move toward the chondrogenic lineage.
Further, the observed phenotypic changes persist even after the
onset of differentiation, suggesting that the increase in Sox9
protein levels may act to enhance subsequent CG.
FGF-2 enhances hMSC CG through both selection- and
priming-based mechanisms
To investigate the mechanism by which FGF-2 enhances CG,
hMSCs were expanded for 2 passages in medium supplemented
with FGF-2 for varying durations of time. Given that a selection-
based mechanism relies on cell proliferation to manifest its effects,
if it were indeed operating, longer exposures to FGF-2 would allow
for the progressive enhancement of CG due to the continual
selection of a subpopulation of hMSCs with inherent chondro-
genic potential. Since hMSCs divide with an average doubling
time of 12–24 hours in response to a mitogenic stimulus [21],
hMSCs were exposed to FGF-2 for 48 hours and 2 passages
(referred to as selection-based conditions). On the other hand, if a
priming-based mechanism were operating, exposing hMSCs to
FGF-2 for short durations of time, where cell proliferation
specifically in response to FGF-2 can be assumed negligible,
would result in an enhancement of CG. In this study, hMSCs were
exposed to FGF-2 for 2 hours prior to the onset of chondrogenic
differentiation (referred to as priming-based condition). As a
control, hMSCs were maintained in basal medium containing 5%
FBS without FGF-2 supplementation. After expansion, hMSCs
were differentiated into the chondrogenic lineage for 21 days and
assessed for gene expression of Sox9, L-Sox5, AGN and Col II (Fig. 3).
For each of the 4 genes, the priming-based condition showed
reduced mRNA transcript levels at Day 7, while the selection-
based conditions showed a trend of enhanced CG. At Days 14 and
21, the gene expression results showed two patterns. For Sox9 and
AGN, the priming-based condition showed a gradual upregulation
in gene expression, culminating in significantly higher mRNA
transcript levels than the control and selection-based conditions by
Day 21, whereas for L-Sox5 and Col II, the selection-based
conditions showed significantly higher mRNA transcript levels
than the priming-based condition and control hMSCs at Days 14
and 21. While insignificant, the priming-based condition also
showed consistently higher L-Sox5 and Col II transcript levels than
the control at Days 14 and 21. Together, these data suggest that
both selection- and priming-based mechanisms are operating to
enhance hMSC CG in response to FGF-2. However, it does not
eliminate the possibility that hMSCs are progressively primed after
longer exposures to FGF-2 or show how FGF-2 regulates hMSCs
for enhanced CG.
FGF-2 primes hMSCs for CG by increasing basal Sox9
protein levels
We next investigated how the phenotype of hMSCs was
modulated by FGF-2 after short exposures prior to chondrogenic
induction. To do so, we maintained hMSCs in basal medium
containing 5% FBS for 2 passages, washed them twice with DPBS
to remove residual growth factors and administered FGF-2. The
control group again received medium containing 5% FBS without
Figure 2. FGF-2 reduces potency and modulates lineage-specific transcription factor expression of hMSCs. Human MSCs were
expanded for 2 passages in 5% FBS with (+) or without (2) FGF-2 supplementation and assayed for gene and protein expression prior to pellet
culture. (A, B, C) Real-time RT-PCR analysis demonstrated that FGF-2-expanded hMSCs significantly downregulated the expression of embryonic
stem cell markers (A), modulated the expression of key lineage-specific transcription factors (B), and upregulated the expression of L-Sox5 (C). All
values were normalized to GAPDH expression and compared to the non-FGF-2-expanded control. Values are represented as mean 6 SD. *p,0.05,
**p,0.005, n=3. (D) Western blot analysis showed that FGF-2-expanded hMSCs exhibited higher Sox9 protein levels than non-FGF-2-expanded
hMSCs prior to CG, and after pellet formation, pSox9 protein levels were present at higher levels. GAPDH was used as a loading control.
doi:10.1371/journal.pone.0022887.g002
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5% FBS with either 5 or 50 ng/mL FGF-2. Remarkably, Sox9
protein levels were elevated in hMSCs prior to differentiation after
just 30 minutes exposure to FGF-2 and persisted for at least
2 hours (Fig. 4A), with hMSCs receiving medium supplemented
with 5 ng/mL FGF-2 showing a larger increase in Sox9 protein
levels than those receiving 50 ng/mL FGF-2. Importantly, hMSCs
receiving 5 ng/mL FGF-2 just 2 hours prior to chondrogenic
induction in pellet culture showed substantially higher pSox9
protein levels 12 hours after chondrogenic induction compared to
non-FGF-2-exposed control hMSCs (Fig. 4B), suggesting that
hMSCs are indeed primed by FGF-2 prior to chondrogenic
induction, and these phenotypic changes are pivotal for enhancing
CG.
Since Sox9 expression has been shown to be upregulated by
TGF-b signaling in a variety of contexts [22,23,24], we explored
whether FGF-2 increases Sox9 expression through crosstalk with
the TGF-b signaling pathway. To do so, hMSCs were treated with
or without 10 mM SB431542, a specific inhibitor of TGF-b
receptor 1 kinase activity, for 15 minutes. Human MSCs were
subsequently cultured in medium containing 5% FBS with or
without FGF-2, TGF-b1, and SB431542 for 2 hours. In the
presence of TGF-b1, gene expression of Smad7, a direct target of
TGF-b signaling, was upregulated, and Smad3 phosphorylation
was induced without affecting total Smad3 protein levels (Fig. 4C).
However, when cotreated with SB431542, Smad7 mRNA and
Smad3 phosphorylation levels were reduced to basal levels,
demonstrating successful knockdown of TGF-b signaling. End-
point PCR and Western blot analysis showed that inhibition of
TGF-b signaling increased Sox9 mRNA and protein levels, while
treatment with TGF-b1 caused a substantial decrease in Sox9
expression. Importantly, treatment with FGF-2 was able to restore
Sox9 protein levels to that in hMSCs treated with SB431542
(Fig. 4C), suggesting that FGF-2 does not increase Sox9 levels
through crosstalk with the TGF-b signaling pathway.
To gain greater mechanistic insight into how FGF-2 regulates
hMSCs after short- and long-term exposure, we analyzed Sox9
protein levels on a per cell basis using flow cytometry after
varying durations of exposure to FGF-2. Flow cytometry analysis
for Sox9 confirmed that expansion of hMSCs in medium
supplemented with FGF-2 increased Sox9 protein levels at all
time points compared to non-FGF-2-exposed control hMSCs
Figure 3. FGF-2 enhances hMSC CG through both selection- and priming-based mechanisms. Human MSCs were expanded for 2
passages in medium supplemented with FGF-2 for varying durations of time and assayed for cartilage-specific gene expression in pellet culture up to
21 days using real-time RT-PCR. Longer durations of FGF-2 exposure during hMSC expansion resulted in the significant upregulation of L-Sox5 and Col
II gene expression, while exposure to FGF-2 for just 2 hours resulted in the significant upregulation of Sox9 and AGN by Day 21. All values were
normalized to GAPDH expression and compared to the non-FGF-2-expanded control at Day 7. Values are represented as mean 6 SD. *p,0.05,
**p,0.005, n=3.
doi:10.1371/journal.pone.0022887.g003
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increased with longer exposures to FGF-2. Further, the flow
cytometry data showed only 1 signal peak in Sox9 fluorescence at
all time points, suggesting that all (or a vast majority of) hMSCs
are responding to FGF-2 with elevated Sox9 protein levels,
whereas multiple diverging signal peaks would be suggestive of a
differential response between subpopulations of hMSCs and thus
a selection-based mechanism (Fig. S1). Together, these data
suggest that hMSCs are continually primed with longer
exposures to FGF-2.
Figure 4. FGF-2 primes hMSCs for CG by increasing basal Sox9 protein levels. (A) Human MSCs were exposed to FGF-2 for 30 minutes or
2 hours and analyzed for Sox9 protein levels prior to pellet culture by Western blot analysis. Exposure to 5 and 50 ng/mL FGF-2 led to increased Sox9
protein levels in a dose-dependent manner. GAPDH was used as a loading control. (B) Human MSCs were exposed to FGF-2 for 2 hours and
chondrogenically-inducedin pellet culture. FGF-2-expandedhMSCs (+) showed elevated pSox9 protein levels by Western blot analysis.GAPDHwas usedas
al o a d i n gc o n t r o l .(C) Human MSCs were treated with or without SB431542 for 15 minutes, exposed to combinations of 5 ng/mL FGF-2, 10 ng/mL TGF-b1
and 10 mM SB431542 for 2 hours, and analyzed for Sox9 mRNA and protein levels by end-point PCR and Western blot analysis, respectively. Exposure to
FGF-2 led to increased Sox9 mRNA and protein levels, while TGF-b1 reduced Sox9 expression. Smad7 gene and pSmad3 protein levels were analyzed to
confirmsuccessfulknockdownofTGF-bsignaling.GAPDHwasusedasaloadingcontrol.(D)HumanMSCswereexpandedinFGF-2forvaryingdurationsof
timeandanalyzedfor Sox9 protein usingflowcytometry.Sox9 protein levels per cellwere elevated at all time points after FGF-2 exposure comparedtothe
control and gradually increased with longer exposures. Values are represented as fluorescence signal to noise ratios using geometric means.
doi:10.1371/journal.pone.0022887.g004
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and non-proliferating hMSCs
To further discriminate between priming- and selection-based
mechanisms, we analyzed Sox9 protein levels in proliferating and
non-proliferating hMSCs upon FGF-2 induction. Elevated Sox9
protein levels in non-proliferating hMSCs would strongly support
the notion that a priming-based mechanism is indeed operating to
enhance CG, as selection relies on cell proliferation to manifest its
effects. To do so, we incubated FGF-2- and non-FGF-2-exposed
hMSCs in 10 mM BrdU, double-stained them for Sox9 and BrdU,
and analyzed them using flow cytometry. Given that hMSCs tend
to show enhanced CG after both short and long durations of
exposure to FGF-2, we hypothesized that both proliferating and
non-proliferating hMSCs respond to FGF-2 by increasing basal
Sox9 protein levels, thus being primed for subsequent CG. After
12 and 24 hours, FGF-2-exposed hMSCs showed a higher
percentage of BrdU
+ hMSCs, indicating a greater proliferative
response (Fig. 5A). FGF-2-exposed BrdU
+ hMSCs showed
marginally elevated Sox9 protein levels after 12 hours (,1.5-fold
increase) and substantially higher Sox9 levels after 24 hours (,3.5-
fold increase) (Fig. 5B) compared to non-FGF-2-exposed BrdU
+
hMSCs. Although the differences in Sox9 protein were not as
significant, FGF-2-exposed BrdU
2 hMSCs also showed higher
Sox9 levels after 12 and 24 hours (,1.3- and 2.1-fold increase,
respectively) (Fig. 5B). Taken together, these data further suggest
that a priming-based mechanism is acting to enhance hMSC CG
in response to FGF-2, with proliferating hMSCs elevating Sox9
protein levels more dramatically.
FGF-2 enhances hMSC CG partially through a Sox9-
mediated mechanism
Finally, to determine whether FGF-2 acts directly through Sox9
to enhance hMSC CG, we used RNA interference (RNAi) to
knockdown Sox9. Human MSCs were electroporated with siRNA
targeted to Sox9, or with non-targeting siRNA as a control, and
then treated with or without FGF-2 24 hours after transfection
(Fig. 6A). 72 hours after transfection, hMSCs were induced into
the chondrogenic lineage for 21 days using pellet culture.
Following transfection, hMSCs displayed a more spindle-shaped
morphology than untransfected cells (Fig. S2) and continued to
proliferate (data not shown). 48 hours after transfection, Sox9 gene
expression was markedly reduced compared to the negative
control, and this correlated to a loss of Col II expression in
undifferentiated hMSCs (Fig. S3). At the time of chondrogenic
induction, Sox9 protein levels were likewise markedly reduced in
Sox9 siRNA-transfected hMSCs (Fig. 6B). Notably, Sox9 siRNA-
transfected hMSCs showed elevated Sox9 protein levels when
treated with FGF-2, exemplifying the potent ability of FGF-2 to
induce Sox9 expression. Despite successfully knocking down Sox9
in both FGF-2- and non-FGF-2-treated hMSCs, a concomitant
decrease in Col II expression was not observed upon chondrogenic
induction (Fig. 6C). Interestingly, FGF-2-pretreated hMSCs still
showed a significant upregulation of Col II gene expression during
differentiation. Taken together, these data suggest that while FGF-
2 consistently leads to elevated Sox9 levels and improved
differentiation, hMSC CG is only partially enhanced by regulating
Sox9 levels.
Discussion
Human MSC-based therapies offer attractive alternatives to
current treatments for cartilage injuries and other debilitating
conditions, such as osteoarthritis, due to the extensive proliferative
capacity of hMSCs and their ability to differentiate into
chondrocytes. However, several challenges could potentially limit
the use of hMSCs to regenerate cartilage. For one, hMSCs
represent a heterogeneous population of cells of varying plasticity
[4,5], thus necessitating the purification of specific subpopulations
with enhanced chondrogenic potential [25]. In addition, hMSCs
lose their differentiation potential upon continued cell passaging
due to the onset of senescence, and even at early passages, these
cells fail to produce the quality and quantity of cartilage matrix
required for tissue engineering applications [6]. To overcome
these limitations, it would be ideal to expand hMSCs in a well-
defined medium containing soluble factors that both select the
correct subpopulation and enhance subsequent differentiation.
In this study, we extended upon previous findings to show that
in addition to selecting a subpopulation of cells with inherent
chondrogenic potential, FGF-2 primed hMSCs to undergo
enhanced CG by increasing basal Sox9 protein levels. In fact,
FGF-2 was remarkably potent at elevating Sox9 levels. Within 30
minutes of exposure to FGF-2, Sox9 levels became elevated
(Fig. 4A), and with continued exposure to FGF-2, Sox9 levels
Figure 5. FGF-2 elevates Sox9 protein levels in both proliferating and non-proliferating hMSCs. Human MSCs were exposed to FGF-2 for
12 and 24 hours in the presence of BrdU, double-stained for Sox9 and BrdU, and analyzed using flow cytometry. (A) FGF-2 exposed hMSCs showed a
higher percentage of BrdU
+ cells than non-FGF-2-exposed hMSCs after 12 and 24 hours. (B) Sox9 protein levels were elevated in both BrdU
+ and
BrdU
2 FGF-2-exposed hMSCs after 12 and 24 hours, with BrdU
+ hMSCs showing more marked differences compared to non-FGF-2-exposed control
hMSCs. Values are represented as fluorescence signal to noise ratios using geometric means.
doi:10.1371/journal.pone.0022887.g005
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Sox9 levels could potentially indicate that proliferating hMSCs
alone respond to FGF-2 by increasing basal Sox9 levels, but
remarkably, non-proliferating hMSCs showed a marked increase
in Sox9 levels, as well (Fig. 5B). Together, these data clearly
demonstrate that FGF-2 increases basal Sox9 protein levels in
hMSCs. Similarly, Murakami et al. found that FGF-2 enhanced
Sox9 gene and protein expression, as well as the activity of a Sox9-
dependent enhancer, in mouse primary chondrocytes and
C3H10T1/2 cells. Further, they showed that the FGF-2-induced
increase in Sox9 expression could be blocked by inhibiting MEK
activity, suggesting that the effects are regulated through the
MAPK pathway. While their study suggested that the increase in
Sox9 was mediated through the MAPK pathway in mouse cells,
Sox9 is likely not a direct downstream target gene of FGF signaling
in hMSCs, as Sox9 gene expression was not upregulated in
response to FGF-2 when de novo protein synthesis was blocked
using cycloheximide (data not shown).
Watanabe et al. showed that there exists a crosstalk between
Smad and MAPK pathways to drive chondrocyte-specific gene
expression in murine ATDC5 cells [26], raising the possibility that
FGF-2 elevates basal Sox9 protein levels through crosstalk with the
TGF-b signaling pathway. Additionally, TGF-b ligands have been
shown to be potent inducers of Sox9 expression in a variety of
cellular contexts [22,23,24]. However, our data showed that FGF-
2 induced Sox9 expression independent of TGF-b signaling. In
fact, TGF-b1 markedly reduced Sox9 expression, thus demon-
strating an inhibitory role for TGF-b signaling in hMSCs cultured
in monolayer. While our work shows an important role for FGF-2
in inducing Sox9 expression, further work is needed to fully
elucidate the underlying signaling mechanism.
Importantly, elevated Sox9 protein levels prior to differentiation
resulted in a concomitant increase in pSox9 protein levels upon
chondrogenic induction (Fig. 2D and 4B), and these increases
correlated strongly with enhanced CG. Sox9, a transcription factor
harboring the conserved high-mobility group DNA-binding
domain, activates chondrocyte-specific marker genes and is thus
critical for differentiation into the chondrogenic lineage [18].
Indeed, in the absence of Sox9, there is a complete blockage of
chondrocyte differentiation in vivo during development [27]. In
vitro, Sox9 has also been shown to enhance chondrogenic
differentiation and redifferentiation. For instance, Tew et al.
transduced normal and osteoarthritic chondrocytes with Sox9 and
measured their ability to reacquire a chondrocytic phenotype after
sequential passage [28]. Sox9 transduction caused a 10-fold
increase in Col II expression in osteoarthritic chondrocytes
compared to GFP-transduced controls in monolayer culture, an
increase that was amplified another 10-fold upon redifferentiation
in pellet culture. Similarly, Kupcsik et al. transduced hMSCs with
Sox9 and observed an increase in cartilage-specific gene expression
upon culture in hydrogel scaffolds without any requirement for
exogenous growth factor supplementation [29]. Sox9 clearly has
an essential role in CG, and here, we identify a growth factor
capable of elevating endogenous Sox9 levels in a physiologically
relevant manner prior to differentiation.
Given the indispensable role of Sox9 in chondrocyte differen-
tiation, it is surprising that knocking down Sox9 expression did not
have an adverse effect on hMSC CG after FGF-2 stimulation.
This may suggest that the increase in Sox9 levels is secondary to
another more direct cellular response, such as cytoskeletal
organization. Previous reports have shown that FGF-2 induces
rapid reorganization of the actin cytoskeleton [30,31], and in
agreement with these findings, our preliminary data show that
FGF-2 significantly upregulates the expression of Rac1 while
significantly downregulating RhoA expression (data not shown).
Furthermore, the organization of the actin cytoskeleton has been
implicated as having a central role in chondrocyte differentiation
[32,33]. For instance, disrupting the actin cytoskeleton of hMSCs
with the actin depolymerizing drug cytochalasin D markedly
enhances differentiation into the chondrogenic lineage [34], and
more recent work has suggested that actin organization regulates
the transcriptional activity of Sox9 through protein kinase A (PKA)
[35]. Taken together, the prochondrogenic effects of FGF-2 may
be regulated only secondarily through Sox9, with more direct
regulation occurring via an actin cytoskeleton-based signaling
mechanism. Given that FGF-2 was able to upregulate Sox9
expression even in Sox9 siRNA-transfected hMSCs (Fig. 6B and
S3) and the transfections were designed to only transiently
knockdown Sox9, it is also possible that the Sox9 knockdown
was lost upon FGF-2 treatment and subsequent chondrogenic
induction, as TGF-b signaling, cell-cell interactions and 3D
environments have all been shown to modulate Sox9 expression
and activity [23,36,37]. Nonetheless, there appears to be a strong
correlation between Sox9 protein levels in hMSCs prior to CG
and their ability to differentiate into the chondrogenic lineage.
Figure 6. FGF-2 enhances hMSC CG partially through a Sox9-
mediated mechanism. (A) RNAi experiments were performed to
knockdown Sox9 expression. Human MSCs were transfected with siRNA
targeted to Sox9 or non-targeting siRNA. 24 hours after transfection,
hMSCs received FGF-2, and 72 hours after transfection, hMSCs were
differentiated into the chondrogenic lineage in pellet culture. Sox9
knockdown was verified 48 and 72 hours after transfection by gene and
protein analysis, respectively. (B) Western blot analysis showed that
Sox9 levels were lower in both FGF-2- (+) and non-FGF-2-treated (2)
hMSCs transfected with Sox9 siRNA compared to untransfected and
non-targeting siRNA-transfected hMSCs. With each treatment, FGF-2
increased Sox9 levels. (C) After transfected hMSCs were differentiated
into the chondrogenic lineage, real-time RT-PCR analysis showed that
knockdown of Sox9 expression did not result in a concomitant decrease
in Col II gene expression 7 and 21 days after pellet formation. However,
FGF-2 pretreatment led to a significant increase in Col II gene
expression in untransfected and Sox9 siRNA-transfected hMSCs.
doi:10.1371/journal.pone.0022887.g006
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medium supplemented with FGF-2 enhances hMSC CG
[8,13,38]. Mastrogiacomo et al. first tested the effect of several
growth factors individually or in combination with FGF-2 on
hMSC CG and osteogenesis and found that FGF-2 had a
dominant effect in enhancing subsequent differentiation. In fact,
differentiation into both lineages was evident only in those cultures
supplemented with FGF-2, suggesting that FGF-2 maintained
hMSCs in an immature state allowing their in vitro expansion and
maintenance of differentiation potential. Similarly, Tsutsumi et al.
found that FGF-2 markedly extended the life span of hMSCs, thus
allowing them to retain their ability to differentiate into
chondrocytes, osteoblasts and adipocytes throughout many mitotic
divisions. Furthermore, Bianchi et al. showed that FGF-2-
supplemented hMSC primary cultures displayed an early increase
in telomere length followed by a steady shortening, whereas non-
FGF-2-supplemented hMSC cultures showed only a steady decline
in telomere length without an initial increase. Since telomerase
activity was not detectable in their hMSC cultures, the group
concluded that FGF-2 selects for the survival and expansion of a
particular subset of cells enriched in multipotent precursors.
Together, these 3 studies strongly support the notion that FGF-2
selects for a subpopulation of hMSCs with enhanced multipotency.
In contrast, our data suggest that FGF-2 actually decreases the
potency of hMSCs, given that hMSCs treated with FGF-2 for 2
passages showed a significant downregulation of Oct3/4 and Nanog
expression (Fig. 2A). In addition, our data suggest that FGF-2
primes hMSCs for lineage-specific differentiation, as hMSCs
maintained in FGF-2-supplemented medium for 2 passages
showed a significant upregulation of Sox9 and L-Sox5 expression
(Fig. 2B and C). Interestingly, FGF-2 progressively increased basal
Sox9 protein levels per cell with longer durations of exposure
(Fig. 4C). Likewise, FGF-2-treated BrdU
+ hMSCs showed an
increase in Sox9 protein levels per cell from 12 to 24 hours. Taken
together, these results suggest that a priming-based mechanism
may be acting to enhance hMSC CG instead of a selection-based
mechanism, or the priming- and selection-based mechanisms are
one and the same. For instance, it is possible that FGF-2 selects a
more youthful cell population to proliferate while concomitantly
priming them for differentiation into specific lineages. The
resulting FGF-2-treated cell population would be younger, as
evidenced by longer telomeres and extended lifespan, but with
reduced potency, reflecting a more restricted gene expression
profile.
In accordance with the study reported by Im et al. [38], we have
shown that culture medium supplemented with FGF-2 greatly
enhances the chondrogenic potential of hMSCs even under
reduced serum conditions. Remarkably, expansion in basal
medium containing 1% FBS with 5 ng/mL FGF-2 was able to
improve the chondrogenic capacity of hMSCs when compared to
standard basal medium containing 10% FBS. Figure 1 clearly
demonstrates the importance of supplementing medium with
FGF-2 when expanding hMSCs for subsequent chondrogenic
differentiation. In addition to enhancing cartilage formation, FGF-
2 has also been shown by several groups to accelerate the
proliferation rate of hMSCs [8,39]. Together, FGF-2 appears to
be a crucial growth factor for the expansion of hMSCs, yielding a
large quantity of quality cells for cartilage tissue engineering
applications.
Conclusion
Our results show that FGF-2 treatment prior to CG is critical to
enhance the differentiation of hMSCs into chondrocytes. FGF-2
was found to be a potent inducer of Sox9 expression, and there is a
strong correlation between Sox9 levels prior to CG and the
effectiveness of differentiation. Thus, FGF-2 primes hMSCs for
enhanced CG, at least in part, by increasing basal Sox9 protein
levels.
Materials and Methods
Ethics Statement
Written consent was obtained from patients by the University of
Wisconsin Hospital to obtain bone marrow-derived hMSCs before
proceeding with total hip replacement surgeries.
Isolation and culture of bone marrow-derived hMSCs
With approval from the Institutional Review Board of the
University of Washington and University of Wisconsin-Madison,
bone marrow-derived hMSCs were isolated from femoral heads of
patients undergoing total hip replacement surgery. Whole bone
marrow was curetted from the interior of the femoral neck and head,
washed in Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco,
Grand Island, NY) and separated from trabecular bone fragments
and other tissues using an 18-gauge needle attached to a 25-mL
s y r i n g e .T h eb o n em a r r o wc e l l sw e re centrifuged at 1,200 rpm for 5
minutes to separate them from residual adipose tissue and
resuspended in Hank’s Balanced Salt Solution (HBSS) (HyClone,
Logan, UT). Mononucleated cells were isolated via Ficoll density
centrifugation at 600 g for 30 minutes and washed in HBSS. Cells
were then resuspended in DMEM with 1 g/L glucose (DMEM-LG)
supplemented with 10% fetal bovine serum (FBS) (Invitrogen,
Carlsbad, CA) from selected lots and 1% antibiotics (10,000 I.U/
mLpenicillin, 10,000 mg/mLstreptomycin,25 mg/mL amphotericin
B) (Mediatech, Manassas, VA) and plated in 75 cm
2 cell culture flasks
(Corning, Corning, NY). Cells were maintained at 37uCi na
humidified environment with 5% CO2.T h ef o l l o w i n gd a y ,c u l t u r e
medium was changed to remove non-adherent cells. Subsequent
medium changes were made every 3 days. Upon 80% confluence,
cells were passaged using 0.05% trypsin/EDTA (Mediatech) and re-
plated at a cell seeding density of 1,000 cells/cm
2. All cells to be used
in studies were frozen in culture medium containing 10% dimethyl
sulfoxide (DMSO) (Sigma, St. Louis, MO). Cells were thawed and
expanded for 2 passages prior to all experiments. During this
expansion phase, cells were generally maintained in DMEM-LG
containing 5% FBS, with or without 5 ng/mLFGF-2 (R&D Systems,
Minneapolis, MN), as this concentration is optimal for hMSC
proliferation and subsequent differentiation [40]. Upon 80%
confluence, hMSCs were either analyzed for their predifferentiation
properties or harvested for pellet culture.
Chondrogenic differentiation of hMSCs in pellet culture
Upon 80% confluence, hMSCs were trypsinized, counted, and
resuspended in serum-free chondrogenic medium composed of
DMEM with 4.5 g/L glucose (DMEM-HG) (Gibco) supplemented
with 1% antibiotics, 1% ITS (BD Biosciences, Franklin Lakes, NJ),
0.9% sodium pyruvate (Sigma), 50 mg/mL ascorbic acid, 40 mg/
mL L-proline, 10
27 M dexamethasone, and 10 ng/mL TGF-b1
(R&D Systems). Aliquots containing 2.5610
5 cells were distributed
in 96-well round-bottomed tube plates and centrifuged at 600 g for
5 minutes. Pellets were cultured in an incubator kept at 37uCi na
humidified atmosphere with 5% CO2. Medium was changed
every 3 days. On Days 7, 14 and 21, cell pellets were harvested
and analyzed for cartilaginous properties.
RNA isolation and RT-PCR analysis
For end-point PCR analysis, total RNA was isolated from
chondrogenic pellets with 1 mL TRIzol (Invitrogen) according to
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chloroform to homogenized samples, RNA was precipitated with
500 mL isopropanol and washed 3 times in 80% molecular biology
grade ethanol. RNA pellets were dissolved in 20 mL DEPC-treated
water. For real-time PCR analysis, total RNA was isolated from
monolayer hMSCs and chondrogenic pellets using RNeasy Kit
(Qiagen, Valencia, CA) according to the manufacturer’s protocol.
In each case, RNA yields were determined based on A260 using
NanoDrop 1000 Spectrophotometer (Thermo Scientific; Wal-
tham, MA). RNA samples with 260/280 measurements below
1.80 were further purified using Qiagen RNeasy Kit. First strand
cDNA was reverse transcribed from 170 ng total RNA for end-
point PCR, and 840 and 160 ng total RNA for monolayer hMSCs
and chondrogenic pellets, respectively, for real-time PCR using
SuperScript III First-Strand Synthesis System (Invitrogen).
For end-point PCR, cDNA was amplified using Eppendorf
Thermal Cycler and Platinum Taq DNA polymerase (Invitrogen)
with the oligonucleotide primers found in Table S1. The following
cycle numbers were used to amplify gene-specific PCR products:
cartilage oligomeric matrix protein (COMP) and collagen type XI,
23; AGN, collagen type X and Sox9, 28; Col II, 30; and col IX,
32. All primer annealing temperatures were optimized empirically,
and products for optimized PCR runs were visualized by agarose
gel electrophoresis to confirm one product of correct size.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression
was used as an internal control to normalize the amount of cDNA
synthesized per sample. Twenty-five cycles were used to amplify
GAPDH. The PCR products were resolved by agarose gel
electrophoresis and visualized by ethidium bromide staining on
Kodak Image Station 4000R Pro.
For real-time PCR, cDNA was amplified using BioRad C1000
Thermal Cycler and iQ SYBR Green Supermix (BioRad,
Hercules, CA) with the oligonucleotide primers found in Table
S1. GAPDH gene expression was used as an internal control to
normalize the amount of cDNA synthesized per sample, and all
values were compared to non-FGF-2-expanded control hMSCs
using the 2
2DDCt method. All primer annealing temperatures were
optimized so that amplification efficiencies fell within 95 and
105%, and single products were confirmed after 40 amplification
cycles at the optimized temperature via agarose gel electropho-
resis.
Protein isolation and Western blot analysis
Cell lysates were prepared from trypsinized monolayer hMSCs
or chondrogenic pellets using RIPA solubilization buffer (50 mM
Tris-HCl (pH 7.5), 1% Nonidet P-40, 0.25% Na-deoxycholate,
150 mM NaCl, 1 mM EDTA, and complete protease inhibitor
cocktail (Roche, Madison, WI)). Chondrogenic pellets needed to
be physically dissociated with a pestle upon addition of
solubilization buffer for more complete protein extraction. After
centrifugation at 14,000 rpm for 10 min at 4uC, the supernatant
was collected and protein concentrations were determined using
BCA Protein Assay Kit (Pierce, Rockford, IL) against a standard
curve of bovine serum albumin. Protein samples were subjected to
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and subsequently transferred onto PVDF membranes for
Western blotting. Membranes were incubated with the following
primary antibodies overnight at 4uC: rabbit polyclonal antibody to
Sox9 (Abcam; Cambridge, U.K.), rabbit polyclonal to Sox9
(phospho S181) (Abcam), rabbit monoclonal to Smad3 (Cell
Signaling; Danvers, MA) and rabbit monoclonal to phospho-
Smad3 (Ser423/425) (Cell Signaling). GAPDH was used as an
internal loading control and detected with a rabbit monoclonal
antibody (Cell Signaling; Danvers, MA). The secondary HRP-
conjugated antibody was goat-anti-rabbit (Cell Signaling). The
membrane was developed using SuperSignal West Pico Chemi-
luminescent Substrate (Pierce) on Kodak Image Station 4000R
Pro.
Glycosaminoglycan quantification
Pellets were digested by papain for 24 hours at 60uC after 7, 14
and 21 days of chondrogenic differentiation. Total sulfated
glycosaminoglycan (GAG) was then quantified using Blyscan
Assay Kit (Biocolor, Westbury, NY) based on 1,9-dimethylmethy-
lene blue binding against a standard curve of chondroitin-6-sulfate
according to the manufacturer’s protocol. Total GAG values were
then normalized to total DNA content using Quant-iT PicoGreen
dsDNA Assay Kit (Invitrogen) in triplicate.
Flow cytometry staining and analysis
Monolayer hMSCs were trypsinized, pelleted and gently
resuspended in ice-cold FACS Buffer (0.1% bovine serum
albumin/0.1% sodium azide in 1x DPBS). Single cell suspensions
were fixed with 2% paraformaldehyde (methanol-free; Poly-
sciences, Warrington, PA) for 10 minutes at room temperature
(RT) in the dark and permeabilized in FACS Buffer with 0.1%
saponin (Sigma) for 15 minutes at RT. Fixed and permeabilized
samples were incubated with the following antibodies for 1 hour at
RT: rabbit polyclonal antibody to Sox9 (Abcam) and rabbit IgG
isotype control (Abcam). Samples were then incubated with PE-
conjugated donkey polyclonal to rabbit IgG secondary antibody
(Abcam) for 30 minutes at RT. Samples were washed 3 times and
resuspended in FACS Buffer. For BrdU-incubated cells, hMSCs
were fixed using FITC BrdU Flow Kit (BD Pharmingen) following
the manufacturer’s protocol. Data was acquired using Benton
Dickinson FACSCalibur cytometer (488 and 633 nm lasers) and
analyzed by dividing the fluorescence intensity geometric means
by the geometric mean of relevant isotype controls to reduce
background fluorescence. For BrdU-incubated cells, gates were
used prior to analysis to differentiate between BrdU
+ and BrdU
2
cells.
RNA interference
ON-TARGETplus SMARTpool siRNA containing a mixture
of 4 SMART selection-designed siRNAs targeting Sox9 was
purchased from Dharmacon (Lafayette, CO). 200,000 hMSCs
were electroporated per 10 mL reaction with Sox9 siRNA
(100 nM) using the Neon Transfection System (Invitrogen).
Transfections with ON-TARGETplus Non-targeting pool (Dhar-
macon) were performed in parallel as a negative control. Optimal
electroporation conditions (1350 V, 20 ms, and 1 pulse) were
determined using siGLO Cyclophilin B control siRNA (Dharma-
con). Effective Sox9 knockdown was validated by assaying Sox9
gene and protein expression 48 and 72 hours after transfection,
respectively.
Statistical analysis
All quantifiable studies were reported as means 6 standard
deviations. Statistical analyses were performed using unpaired
Student’s t-test. P-values #0.05 were considered significant.
Supporting Information
Figure S1 FGF-2 primes hMSCs for CG by increasing
basal Sox9 protein levels. Human MSCs were maintained in
FGF-2 for varying durations of time and analyzed for Sox9 protein
using flow cytometry. Flow cytometry histograms showed a larger
shift in fluorescence intensity for hMSCs exposed to FGF-2 (right
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panel) at each time point. The shift in fluorescence intensity
gradually increased with culture time, and there was only a single
peak (shaded gray) in fluorescence intensity at each time point.
Fluorescent peaks are plotted against the isotype control peak
(unshaded).
(TIF)
Figure S2 FGF-2 enhances hMSC CG partially through a
Sox9-mediated mechanism. Transfected hMSCs were more
spindle-shaped than untransfected hMSCs 24 hours after trans-
fection. Scale bar represents 25 mm.
(TIF)
Figure S3 FGF-2 enhances hMSC CG partially through a
Sox9-mediated mechanism. Sox9 siRNA-transfected hMSCs
(dark gray) showed reduced Sox9 and Col II gene expression
48 hours after transfection compared to untransfected (white) and
non-targeting siRNA-transfected hMSCs (gray) using real-time
RT-PCR analysis.
(TIF)
Table S1 List of end-point and real-time RT-PCR primers.
(TIF)
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